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AbstrAct
background The hereditary spastic paraplegias 
(HSPs) are a rare and heterogeneous group of 
neurodegenerative disorders that are clinically 
characterised by progressive lower limb spasticity. They 
are classified as either ‘pure’ or ‘complex’ where spastic 
paraplegia is complicated with additional neurological 
features. Mutations in the spastin gene (SPAST) are the 
most common cause of HSP and typically present with a 
pure form.
Methods We assessed in detail the phenotypic and 
genetic spectrum of SPAST-related HSP focused on 118 
patients carrying SPAST mutations.
results This study, one of the largest cohorts 
of genetically confirmed spastin patients to date, 
contributes with the discovery of a significant number 
of novel SPAST mutations. Our data reveal a high rate 
of complex cases (25%), with psychiatric disorders 
among the most common comorbidity (10% of all 
SPASTpatients). Further, we identify a genotype–
phenotype correlation between patients carrying loss-
of-function mutations in SPAST and the presence of 
psychiatric disorders.
IntroductIon
The hereditary spastic paraplegias (HSPs) are a 
rare and heterogeneous group of neurodegenera-
tive disorders characterised by slowly progressive 
lower limb spasticity1 with a prevalence that varies 
from 1.2 to 9.6 per 100 000.2 HSPs are classified 
as ‘pure’ when spastic paraplegia is the only clinical 
feature or ‘complex’ when is associated with other 
symptoms.3
Mutations in >70 distinct loci (SPG 1–72) and 
>50 genes have been identified in patients with 
HSPs.4 5 Mutations in the spastin gene (SPAST) are 
the most common cause of HSP, accounting for 
45% of all autosomal-dominant forms.6 7 SPAST is 
an ATPase, belonging to the AAA family, involved 
in microtubule dynamics.8 9 All types of mutations 
have been described in SPAST with missense muta-
tions clustered mainly in the AAA domain, while 
nonsense, splice-site mutations and insertions/dele-
tions can be found in different locations throughout 
the gene.10 
Clinically, SPAST is most often associated with a 
pure form of HSP. Complex phenotypes have been 
rarely described in SPAST and include seizures, intel-
lectual disability and cerebellar ataxia.11–13 Neuro-
psychiatric comorbidities have only been reported 
in one study, where a higher-than-expected rate 
of psychosis was found in individuals with HSPs 
including SPAST;14 however, the association with 
spastin was uncertain. Depression is reported to be 
frequent (41%) but unrelated to disease severity.15 
No clear correlation between type or location of the 
mutation and SPAST phenotype has been reported.
The clinical and genetic description, together 
with a detailed genotype–phenotype correlation in 
HSPs, is often limited due to small sample sizes of 
patients reported. We present here the results from 
one of the largest clinical and genetic cohorts of 
patients carrying SPAST mutations.
MAterIAls And Methods
sample group
A totalof 118 patients from 104 families from the 
UK population referred as SPAST positive to the 
National Hospital for Neurology and Neurosurgery 
in London, a national referral centre for HSP.
Genotype
Blood samples for DNA testing were collected with 
informed consent. Screening for point mutation in 
SPAST gene was undertaken by gene fluorescent 
DNA sequencing. Screening for whole-exon dele-
tion and duplication was undertaken by Multiplex 
Ligation-dependent Probe Amplification analysis. 
For each reported mutation, we confirmed patho-
genicity and novelty. For missense variants, predic-
tion was based on residue conservation across 
different species and by looking at previously 
described mutations in the same residue. Frameshift 
and nonsense mutations as well as large deletions 
are predicted to result in the production of unstable 
messenger RNAs (mRNAs), truncated or absent 
proteins and were considered likely pathogenic. 
For splice-site mutation, in silico analysis software 
was used (Alamut) to determine whether the variant 
affects normal pre-mRNA splicing via disruption/
creation of splice-site consensus sequences (http://
www. interactive- biosoftware. com). The numbering 
of mutations in the text is consistent with GenBank 
(accession number NM_014946.3 for complemen-
tary DNA, NG_008730.1 for gene).
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Phenotype
Detailed phenotypic data were retrospectively collected through 
a series of standardised forms including patient history, neuro-
logical examination and instrumental evaluations for each 
patient carrying SPAST pathogenic variants.
Comprehensive phenotypic data were available for 84 cases. 
Onset before and including 20 years old was defined as early 
onset as a generally recognised standard.3 Pure phenotype was 
defined as HSP characterised by corticospinal tract syndrome 
(CTS), with sphincter involvement and vibration loss accepted 
as additional features. Complex phenotype was defined as cases 
with CTS, plus at least one other symptom that cannot otherwise 
be explained by associated conditions.
Disability score was defined as: 0, asymptomatic; 1, able 
to walk but difficult to run; 2, uses one stick and/or orthosis; 
3, uses two sticks/walker; 4, unable to walk, uses wheelchair. 
The rate of disease progression was calculated by dividing the 
current disability score by the disease duration and presented in 
percentage per year.
Disease severity was assessed using the Spastic Paraplegia 
Rating Scale (SPRS).16 We had information available to complete 
the SPRS for 33 cases. Spasticity was assessed using the modified 
Ashworth Scale (AS) (0–4).17 Quantification of spasticity was 
possible in 59 cases. Muscle power was measured according to 
the Medical Research Council muscle scale (0–5).
Psychiatric comorbidities were formally diagnosed and 
followed up by the mental health team for all but one symp-
tomatic case reported here. Non-symptomatic patients have not 
been routinely screened by a psychiatrist specialist.
statistical analysis
The distribution of severity score and disease progression rate 
by genotype was determined using a t-test. Univariate analysis 
of variance was performed for the correlation between age at 
onset (AAO) and genotype. A t-test was carried out to analyse 
mean AAO and gender and correlation between AAO and mode 
of inheritance (maternal/paternal). Kruskal-Wallis analysis of 
variance was used for analysing non-parametric values such as 
correlation between mutation type/functional domain/AAO/
gender and disease progression, disability score, AS and SPRS. 
p≤0.05 was the significance level used for statistical analysis. 
We used the SPSS (version 23.0) software for statistical analysis.
results
Genetic spectrum
We identified 118 cases from 104 families carrying SPAST vari-
ants. A total of 72 unique pathogenic variants were identified, 
of which 40.3% were novel (table 1) and 59.7% previously 
described (see online supplementary table e1). Ten cases carried 
variants of which the causal proof to HSP could not be estab-
lished, including the previously described HSP phenotypic modi-
fier p.Ser44Leu; these were removed from further analysis (see 
online supplementary table e2). The polymorphism p.Ser44Leu 
was found in five cases, three of which had a second SPAST 
pathogenic variant (alleles frequency 5/216, 0.2%) in keeping 
with the Minor allele frequency of 0.9% reported in Euro-
pean/Americans in Exome Variant Server. The vast majority of 
mutations were unique to one kindred (82%) and only 13 were 
recurrent. The most frequent mutation is the p.Arg460Cys iden-
tified in five unrelated families (5.3%). All types of mutations 
were identified. Missense mutations represented 39%. Loss-of-
function mutations represented 61% including framshift 22%, 
splicing 17%, nonsense 7%, inframe deletions 3%, duplications 
1% and large whole-exon deletions 11%. While loss-of-function 
mutations are scattered throughout SPAST, all missense muta-
tions are located in the AAA domain, with only one exception 
(the p.Ile328Lys) (figure 1).
All cases included in this study had a single heterozygous 
mutation except case 62, which carries two heterozygous 
missense mutations (p.Arg372Thr, p.Asn579His), and case 3, 
which was found to carry two in-cis mutations (p.Arg364Met, 
p.Pro365Ser). In case 62, we did not have DNA from any other 
family members and we were unable to establish if the two 
mutations were inherited in-cis or in-trans, but p.Asn579His has 
previously been reported as pathogenic both in association with 
a second mutation18 and in isolation.19 One case (37) presenting 
with two concurrent autosomal-dominant mutations (SPAST and 
OPMD) was described in details here20 and was removed from 
further phenotype analysis.
clinical features
The mean AAO was 29.2±16.2 years with a range from birth 
to 63 years (figure 2A), with high variability between and 
within the families. Within families, a significantly earlier onset 
was observed in the offspring of affected parents (p=0.02) 
(figure 2B); however, we attribute this to recall and ascertain 
bias. Early onset, defined as onset before 20 years of age, was 
identified in 32.1%. There was no statically significant correla-
tion between AAO and mutation type (figure 2C). However, it 
was noted that missense mutations were responsible for 33% of 
early-onset HSP and 46% of cases when AAO was ≤10 years 
(figure 2D). Onset before 10 years was identified in 14 patients 
(16%).
The summary demographic data are presented in figure 3A. 
The most common symptom at onset was related to lower limbs 
spasticity in the vast majority of cases. It included walking diffi-
culty (38%), leg stiffness (23%), limping and tripping (18%), 
tip-toe walking (8%) and back pain (6%) (figure 3B). One case 
initially reported neurogenic bladder (case 30) and another 
presented with delayed walking and learning difficulties (case 52 
carried a whole-gene deletion).
Examination of the lower limbs was suggestive of a pyra-
midal syndrome with spasticity being more marked than weak-
ness. Spasticity measured with AS revealed an average spas-
ticity score of 1.8, while muscle power measured with Medical 
Research Council muscle scale revealed an average of 4/5 in 
a pyramidal pattern. Lower limbs sensory loss was present in 
30% of patients and consisted mainly of decreased vibration 
sense.
Disease severity was measured with the SPRS, which revealed 
a mean score of 24.8 (of max 52), consistent with moderate 
severity. While there was no significant difference between SPRS 
and mutation type, a trend was observed between SPRS and age 
at onset (AAO): a higher SPRS score was observed in the late-
onset group (mean SPRS score 26.2) compared with the early-
onset (0–20 years AAO) (mean SPRS=21.5).
The mean disability score was 2.1. There is no significant 
difference between disability score and type of mutation. The 
mean rate of disease progression was 0.12%/year (SD ±0.12%) 
ranging from 0.01%/year to 0.57%/year, confirming a slow, but 
progressive course of the disease. By correlating disease progres-
sion with AAO, it was observed that later AAO (>40 years) is 
associated with a higher progression rate of the disease (p=0.01) 
(figure 3C).
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Pure versus complex phenotype
Pure phenotype was present in 74% of cases consisting of slowly 
progressive lower limb spasticity and weakness. Of note, neuro-
genic bladder was reported in 58% of patients while neurogenic 
bowel symptoms were present in 26% of all patients.
Complex phenotype was identified in 26% of patients and 
presented as CTS plus cerebellar syndrome, peripheral neurop-
athy, learning disability, memory problems and psychiatric symp-
toms (table 2). Interestingly, 10.7% of patients (nine cases from 
seven different families) presented with an associated psychiatric 
illnesses. Three cases had autism spectrum disorders; three cases 
had a diagnosis of severe depression and single cases each had 
borderline personality disorder, hypomania and schizoaffective 
disorder, respectively. Of note, eight out of nine patients affected 
by psychiatric comorbidities carry loss-of-function mutations 
most of which located in the AAA domain. Strikingly, one muta-
tion leading to premature stop codon (c.1635_1636insAA, p.Gly-
546Lysfs*5) was identified in four cases from three families. This 
is one of the few recurrent mutations in our cohort (frequency of 
4.7%) and is fully penetrant for psychiatric comorbidities.
Assessment of cognitive function revealed two cases of mild 
learning disability (cases 82 and 20) and three cases of memory 
impairment (case 75 is 46 years of age, case 41 is 62 years of 
age and case 21 is 77 years of age). One case underwent formal 
neuropsychology assessment, which revealed cognitive impair-
ment affecting frontal and temporal functions. All three muta-
tions associated with memory impairment in our cohort are 
missense variants located in the highly conserved AAA domain.
Nerve conduction studies were conducted in 34 patients (see 
online supplementary table e3) and identified axonal peripheral 
polyneuropathy in 23.5% with chronic denervation on Electro-
myography in 16% of cases. One case (80) showed slow motor 
conduction velocities approaching the demyelinating range. 
However, a selective bias cannot be excluded. Brain MRI was 
available in 45 cases and was normal in 85%. In the remaining 
16%, 9% had mild-to-moderate thinning of the corpus callosum; 
one case had mild cerebellar atrophy (case 113), one had cysts 
in the posterior fossa (case 69) and one asymmetrical volume 
loss in the right hemisphere and midbrain (case 41) (see online 
supplementary figure e1). MRI of the spinal cord was performed 
in 10 patients with 8 of them reported as normal cord or degen-
erative changes only. Only two cases were reported with thin-
ning of the spinal cord. There was no correlation between MRI 
changes and complex phenotypes.
Other neurological comorbidities in association with HSP 
identified in our cohort were single cases of confirmed secondary 
progressive Multiple Sclerosis, congenital torticollis, neurofibro-
matosis, schwannoma and cluster headache.
dIscussIon
In the present cohort, we identified 72 unique pathogenic SPAST 
mutations in 108 cases from 94 British families, confirming 
previous results that recurrent mutations in SPAST are not 
common.21 All types of variants were identified, almost half 
of the patients presenting missense mutations. Our cohort 
confirms22 that the majority of missense mutations are found in 
the AAA domain confirming the importance of AAA cassette for 
SPAST function.10 23 This was linked with a possible dominant 
negative effect of these missense mutations on the gene func-
tion.9 In our study, when p.Ser44Leu phenotypic modifier was 
associated with a second proven causative mutation (case 44), 
it produced an early AAO (11 years) with a complex phenotype 
with a disability score of 4/4.
With >30% of patients presenting an early onset, including 
16% before the age of 10, this study and recent research22 
Figure 1 Schematic representation of SPAST with all the mutations identified in our study. The exons are represented approximately to scale. a blue line 
between exons represents the introns. The SPAST functional domains are indicated: blue, N-terminal sequence; purple, microtubule interacting and trafficking 
domain (MIT); pink, microtubule-binding domain (MTBD); green, aaa (aTPase associated with various cellular activities). Novel mutations are plotted on top 
of the gene; known mutations are below the gene. Types of different mutations are represented as per legend. Interrupted lines show the exons involved in 
large deletions.
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contradict the previous suggestion that spastin causes almost 
exclusively a late-onset HSP. Half of these cases were caused by 
highly disruptive, structural variation mutations. As SPAST-re-
lated HSP is considered an adult onset disease, these cases 
present a big challenge to differentiate with SPG3A (a predom-
inantly pure HSP, where 80% of cases present before the first 
decade of life) and only the genetic testing can provide the defin-
itive diagnosis.
Most importantly, we report over a quarter of our SPAST 
cases presenting a complex HSP phenotype, with >10% 
presenting with an associated psychiatric diagnosis. Psychiatric 
manifestations in HSP were previously described as very rare 
and only in single reports11 of unipolar depression, migraine 
or euphoria.24 25 Depression was the most common mood 
disorder associated with HSP in a previous study described as 
mild to moderate and only single cases of severe depression 
have been reported.15 We present three cases (3.5%) of severe 
depression requiring treatment under the mental health team 
and single cases of borderline personality disorder, hypomania 
and schizoaffective disorder. Manic and affective disorders 
are very rare in HSP.26 27 There was an association between 
SPAST and psychosis in an Irish cohort;14 but with a small 
number of cases (48) and psychotic disorders being fairly 
common in general population (1% in schizophrenia), these 
results could be associated to chance. Nevertheless, both our 
study and the Irish one show an increased rate of psychiatric 
illnesses in spastin patients and further prospective studies 
using detailed psychiatric assessments are necessary to estab-
lish a correlation. More surprisingly, we found that 3.5% of 
cases in our cohort had an autistic spectrum disorder; all diag-
nosed by psychiatrists according to internationally approved 
diagnostic criteria. To our knowledge, there are no reports of 
table 1 Description of all likely pathogenic novel mutations identified in this study
Family 
number cdnA change Amino acid change e/I conclusion evidence
7 c.282_322del41 p.Ala96fs E 1 Likely pathogenic Frameshift
9 c.474delA p.Gly159Glufs*2 E 2 Likely pathogenic Frameshift
97 c.463_465del p.155_155del E2 Likely pathogenic Frameshift
3 c.696insC p.Arg235Lysfs*9 E 5 Likely pathogenic Frameshift
12 c.831_835del5 p.Val278Thrfs*11 E 5 Likely pathogenic Frameshift
15 c.871-2A>G p.? I 5 Likely pathogenic Affects essential splice site. In silico splicing tools predict an effect on 
splicing
16 c.983T>A p.IIe328Lys E 6 Likely pathogenic Novel missense mutation at highly conserved amino acid. SIFT and 
PolyPhen predict to be pathogenic
24 c.1102T>G p.Phe368Val E 8 Likely pathogenic Novel missense mutation at highly conserved amino acid. SIFT and 
PolyPhen predict to be pathogenic
25 c.1104C>A p.Phe368Leu E 8 Likely pathogenic Novel missense mutation at highly conserved amino acid. Different 
substitution at same amino acid previously reported (HGMD 
CM114203)
26 c.1156A>T p.Asn386Tyr E 8 Likely pathogenic Novel missense mutation at highly conserved amino acid
28 c.1115G>C Arg372Thr E 8 Likely pathogenic Novel missense mutation at highly conserved amino acid. Different 
substitution at same amino acid previously reported (HGMD 
CD021854, HGMD CI090392)
29 c.1130G>C p.Gly377Glu E 8 Likely pathogenic Novel missense mutation at highly conserved amino acid. Different 
substitution at same amino acid previously reported (HGMD 
CM114634)
32 c.1169T>C p.Met390Thr E 8 Likely pathogenic Novel missense mutation at highly conserved amino acid
33 c.1174–1G>A p.? I 8 Likely pathogenic Affects essential splice site. In silico splicing tools predict an effect on 
splicing.
44 c.1253A>C p.Glu418Ala E 10 Likely pathogenic Novel missense mutation at highly conserved amino acid
55 c.1406delT p.Phe469Leufs*14 E 11 Likely pathogenic Frameshift
56 c.1408G>T p.Asp470Tyr E 11 Pathogenic Novel missense mutation at highly conserved amino acid. SIFT and 
PolyPhen predict to be pathogenic. Segregated in other family members
57 c.1442_1443insA p.Val482Cysfs*6 E 12 Likely pathogenic Frameshift
58 c.1453G>A p.Ala485Thr E 12 Likely pathogenic Novel missense mutation at highly conserved amino acid
59 c.1493+2_1493+5delTAGG p.? I 12 Likely pathogenic In silico splicing tools predict donor splice site abolished
61 c.1493G>T p.Arg498Met E 12 Likely pathogenic Novel missense mutation at highly conserved amino acid. Different 
substitution at same amino acid previously reported (HGMD 
CM063165)
63 c.1535_1536+1delAGG p.Glu512Aspfs*7 E 13 Likely pathogenic Frameshift
66 c.1635_1636insAA p.Gly546Lysfs*5 E 15 Likely pathogenic Frameshift
68 c.1636G>T p.Gly546X E 15 Likely pathogenic Frameshift
70 c.1664delA p.Asp555Valfs*10 E 15 Likely pathogenic Frameshift
84 c.1729–20T>G p.? I 16 Likely pathogenic In silico splicing tools predict cryptic splice site activated
88 Duplication of exon 1 p.? E 1 Pathogenic Disruption leading to severe protein alteration
96 Deletion of exons 2–9 p.? – Pathogenic Disruption leading to severe protein alteration
92 Deletion of exons 1–16 p.? – Pathogenic Disruption leading to severe protein alteration
cDNA, complementary DNA; E, exon; I, intron.
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an association between autism and spastin or HSP. It is esti-
mated that about 1% of the UK population suffers from an 
autism spectrum disorder28 well below the rate associated with 
spastin in our series. Interestingly, we found one causal muta-
tion associated with psychiatric illness and SPAST-related HSP 
that had an unusual high frequency of 3.5% in our cohort. 
The novel c.1635_1636insAA frameshift was identified in four 
cases from three families. Of note, the vast majority of the 
mutations associated with psychiatric manifestations are loss-
of-function mutations affecting the AAA functional domain.
Figure 2 Mutation spectrum in SPAST-related hereditary spastic paraplegia (HSP). (a) age at  onset (aaO) within families. (B) correlation between the 
aaO within families with a regression line. The first part of the graph shows the aaO between siblings, the middle part of the graph shows aaO when the 
disease is inherited from the father and the last part of the graph shows the aaO when the disease is inherited from the mother. (c) aaO by mutation type. 
(D) Frequency of different mutation types in early-onset spastin HSP cases.
Figure 3 clinical spectrum of SPAST-related hereditary spastic paraplegia. (a) Demographics of the SPAST cohort. (B) Symptoms of onset in SPAST 
patients. (c) correlation between rate of disease progression and age at onset (aaO). aaO >41 was associated with a higher rate of progression (p=0.01).
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So far, there is no strong evidence from Genome Wide Asso-
ciation Study or Copy Number Variants studies for autism loci 
found near or comprising SPAST.29 30 A recent study showed 
that inherited Single Nucleotide Variants that produce truncated 
proteins are more frequent in autistic probands and are in genes 
that are intolerant for functional variations.31 Furthermore, they 
found one case with autism and truncating Single Nucleotide 
Variants in the exon 5 of SPAST.31
The mechanism behind the psychiatric manifestations in HSP 
remains unclear but it has been associated with thalamic hypoper-
fusion,32 thin corpus callosum or white matter abnormalities.33 
Cysts in the posterior fossa have been previously reported in 
SPAST cases.34 Nevertheless, these data should be cautiously 
interpreted as some of these changes could reflect developmental 
rather than neurodegenerative changes and studies with long-
term follow-up will be useful in distinguishing between the two, 
such as serial MRIs in assessing thinning of the corpus callosum. 
Also, we had formal neuropsychiatry assessment for the symp-
tomatic cases only, limiting our ability to comment on the extent 
of psychiatric comorbidities and spastin. However, our study 
warrants further investigations and future studies would have to 
systematically screen spastin patients with a uniform evaluation 
in order to validate the findings.
In our cohort, we report 4.7% of patients with genetically 
diagnosed spastin mutation and learning disabilities and 3.5% 
of seizures. Interestingly, all three cases with seizures reported 
in our study were associated with cognitive deficit. Very few 
reports describe this association and SPAST .35
We also identified memory impairment in 3.5% of cases. 
We are limited in our ability to further describe them due to 
the lack of any histopathological diagnosis in these cases. The 
association between HSP and dementia could be explained by 
coincidence given the small numbers and no extensive neuro-
pathology studies in all reported series. A small number of 
neuropsychology reports have associated spastin with subcor-
tical dementia,12 36 correlating with age, but not with the degree 
of spasticity. Genotypes of the reported families with cognitive 
decline and spastin included missense mutations (Ala139Gly)37 
as well as large deletion of exon 17.38 One SPAST-affected family 
has been previously reported in the literature as having a very 
unusual tau pathology on postmortem brain biopsy.37 As spastin 
does not limit lifespan, caution is required when interpreting 
postmortem results as some changes can be age related or due to 
concurrent diseases.
Correlation between mutation type and phenotype has not 
been reported so far. We show that although not statistically 
significant, there is a trend of earlier AAO associated with large 
deletions, splicing and missense mutations. We confirm that a 
later AAO is associated with a higher rate of disease progression 
as previously reported3 10 and a higher degree of spasticity. There 
was no other genotype–phenotype correlation.
Our study confirms previous reports that polyneuropathy 
associated with SPAST is predominantly axonal motor neurop-
athy with only mild slowing of conduction velocities.39 40
This study, one of the largest cohorts of genetically confirmed 
spastin patients to date, contributes with the discovery of a 
table 2 Description of all complex SPAST cases
case 
number cdnA change Mutation type cts Pn Psychiatric comorbidity other
52 Deletion of exons 1–17 Whole coding SPAST 
sequence deletion
+ – Autism spectrum disorder –
75 c.1408G>T Missense + SM PN Autism spectrum disorder Memory impairment, dysphagia, seizures
43 c.1635_1636insAA Frameshift + – Asperger –
59 c.1805_1808dup AAGC Frameshift + M PN Severe depression under 
mental health team
Paraspinal schwannoma
94 c.1684C>T Nonsense + – Severe depression Congenital torticollis, pes cavus
87 c.1635_1636insAA Frameshift + – Severe depression, gender 
identity disorder
–
54 c.1635_1636insAA Frameshift + – Schizoaffective disorder –
7 c.1635_1636insAA Frameshift + – Abnormal behaviour, not 
formally diagnosed by 
mental health team yet
–
53 c.1174–1G>A Splicing + – Hypomania –
82 Duplication of exon 1 Duplication + SM PN – Mild learning disability
41 c.1082C>T Missense + – – Memory impairment, dysarthria, 
neurofibromatosis type 1
20 c.1728+2T>C Splicing + – – Learning disability, seizures, periodic 
movements of sleep
21 c.1728+2T>C Splicing + – – Memory impairment
26 c.1728+2T>C Splicing + SM PN – –
58 c.1004+2T>A Splicing + Axonal neuropathy 
on nerve biopsy
– –
19 c.1728+1G>T Splicing + M PN – –
66 c.1676insG Frameshift + SM PN – –
80 c.1684C>T Nonsense + M PN – –
83 Duplication of exon 1 Duplication + S PN – Seizures
117 Deletion of exons 10–12 Large deletion + – – Seizures
60 c.1378C>T Missense + – – Ataxia, broken pursuit
+, present; –, absent; cDNA, complementary DNA; CTS, corticospinal tract syndrome; M, motor; PN, peripheral neuropathy; S, sensory.
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significant number of novel SPAST mutations and demonstrates 
the high genotype–phenotype variability in the disease. Most 
importantly, it highlights the high prevalence of psychiatric 
comorbidities in patients with HSP caused by a SPAST muta-
tion. Of note, the previously under-recognised association with 
autism and psychiatric illness needs to be confirmed in other 
cohorts and genes to determine if this is a specific effect of SPAST 
mutations.
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